How to Trip Rapid Review

Step 1: Select articles relevant to your search (remember the system is only optimised for single intervention studies)

Step 2: press

Step 3: review the result, and maybe amend the or if you know better! If we're unsure of the overall sentiment of the trial we will display the conclusion under the article title. We then require you to tell us what the correct sentiment is.

1,976 results for

Multiple Endocrine Neoplasia Type 1

by
...
Alerts

Export results

Use check boxes to select individual results below

SmartSearch available

Trip's SmartSearch engine has discovered connected searches & results. Click to show

181. Multiple Endocrine Neoplasia (Diagnosis)

Multiple Endocrine Neoplasia Updated: Oct 11, 2017 Author: Alicia Diaz-Thomas, MD, MPH; Chief Editor: Robert P Hoffman, MD Share Email Print Feedback Close Sections Sections Pediatric Multiple Endocrine Neoplasia Overview Background First reported in 1963 by Wermer, multiple endocrine neoplasia (MEN) syndromes, found in pediatric and adult patients, consist of rare, autosomal dominant mutations in genes that regulate cell growth. [ ] Current classification recognizes type 1 and , with the latter being (...) mutations of the MEN1 gene in familial multiple endocrine neoplasia type 1 and related states. Hum Mol Genet . 1997 Jul. 6(7):1169-75. . Trouillas J, Labat-Moleur F, Sturm N, Kujas M, Heymann MF, Figarella-Branger D, et al. Pituitary tumors and hyperplasia in multiple endocrine neoplasia type 1 syndrome (MEN1): a case-control study in a series of 77 patients versus 2509 non-MEN1 patients. Am J Surg Pathol . 2008 Apr. 32(4):534-43. . Kloos RT, Eng C, Evans DB, et al. Medullary thyroid cancer: management

2014 eMedicine Pediatrics

182. High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. (Full text)

High penetrance of pheochromocytoma in multiple endocrine neoplasia 2 caused by germ line RET codon 634 mutation in Japanese patients. The precise penetrance of pheochromocytoma (PHEO) in multiple endocrine neoplasia type 2 (MEN2) has not been reported in a large cohort. In this study, we aimed to clarify the codon-specific penetrance of PHEO in MEN2.We established a study group designated the 'MEN Consortium of Japan' in 2008 and asked physicians and surgeons to provide clinical and genetic

2013 European Journal of Endocrinology PubMed abstract

183. Peak Incidence of Pheochromocytoma and Primary Hyperparathyroidism in Multiple Endocrine Neoplasia 2: Need for Age-Adjusted Biochemical Screening. (Full text)

Peak Incidence of Pheochromocytoma and Primary Hyperparathyroidism in Multiple Endocrine Neoplasia 2: Need for Age-Adjusted Biochemical Screening. In multiple endocrine neoplasia type 2, American Thyroid Association (ATA) management guidelines recommend continuous biochemical screening for pheochromocytoma and/or primary hyperparathyroidism. This implicit assumption of linear tumor development is difficult to reconcile with current thinking that cells accrue somatic mutations stochastically (...) , yielding a bell-shaped distribution.This investigation aimed at evaluating the age distribution of pheochromocytoma and primary hyperparathyroidism in gene carriers at risk of developing multiple endocrine neoplasia type 2.ATA class D, C, B, and A mutations, with or without pheochromocytoma and/or primary hyperparathyroidism, were plotted against carrier age at the time of diagnosis or last follow-up.The setting was a surgical referral center.Included were 474 carriers of ATA class D (37 patients), C

2013 Journal of Clinical Endocrinology and Metabolism PubMed abstract

184. Surgical Curability of Medullary Thyroid Cancer in Multiple Endocrine Neoplasia 2B: A Changing Perspective. (Abstract)

Surgical Curability of Medullary Thyroid Cancer in Multiple Endocrine Neoplasia 2B: A Changing Perspective. This investigation aimed at exploring the suitability of nonendocrine manifestations preceding medullary thyroid cancer (MTC) for early diagnosis of multiple endocrine neoplasia type 2B (MEN 2B).MEN 2B patients, running a high risk of metastatic MTC, must be diagnosed early for biochemical cure.Forty-four MEN 2B patients carrying inherited (3 patients) and de novo (41 patients) M918T RET (...) mutations were examined for signs and symptoms prompting MEN 2B.All 3 patients with inherited mutations were diagnosed before the age of 1 year and cured of their C-cell disease. Among 41 patients with de novo mutations, MEN 2B was diagnosed in 12 patients after recognition of nonendocrine manifestations [intestinal ganglioneuromatosis (6 patients), oral symptoms (5 patients), ocular ("tearless crying") (4 patients), and skeletal stigmata (1 patient) alone or concomitantly]. In the remaining 29 patients

2013 Annals of Surgery

185. The role of endoscopy in the evaluation and management of patients with solid pancreatic neoplasia

endocrine neoplasia type 1 syndrome. 103 The majority (50%-60%) of pancreatic NETs are nonfunctioning. 104 Nonfunctioning NETs present with a pancreatic mass, and their presentation may mimic that of adenocarcinoma, although biliary obstruction is uncommon. Functioning NETs are classi?ed according to the hormone secreted by the tumor and include insulinomas, gastrinomas, VIPomas, glucagonomas, and somatostatinomas, and they may present with their associated hormone syndromes. Histologically, NETs (...) , benign or malignant, and arising from the exocrine or endocrine pancreas. The most common and potentially serious solid lesion of the pancreas, pancreatic adenocarcinoma, arises from the exocrine pancreas. An algorithm of the recommended approach to pancreatic adenocarcinoma diagnosis and staging is presented in Figure 1. PRESENTATION AND CLINICAL EVALUATION Patients with suspected solid pancreatic neoplasia may present with obstructive jaundice, abdominal pain, anorexia, weight loss, acute

2016 American Society for Gastrointestinal Endoscopy

186. Multiple endocrine neoplasia: the Chilean experience (Full text)

Multiple endocrine neoplasia: the Chilean experience Multiple endocrine neoplasia (MEN) types 1 and 2 are genetic diseases that are inherited as autosomal traits. The major clinical manifestations of multiple endocrine neoplasia type 1 include the so-called "3 P's": parathyroid, pituitary, and pancreatic tumors, including gastroenteroneuroendocrine tumors. Genetic testing can be performed on patients and the potential carriers of the menin gene mutation, but the genotype-phenotype correlation (...) in multiple endocrine neoplasia type 1 is less straightforward than multiple endocrine neoplasia type 2. Most likely, the main advantage of genetic testing in MEN1 is to exclude from further studies those who are negative for the genetic mutation if they belong to a family with a known history of MEN1. In Chile, we started with rearranged during transfection proto-oncogene genetic testing (MEN2) 15 years ago. We carried out a prophylactic total thyroidectomy to prevent medullary thyroid carcinoma

2012 Clinics PubMed abstract

187. Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2 (Full text)

Molecular mechanisms of RET receptor-mediated oncogenesis in multiple endocrine neoplasia 2 Multiple endocrine neoplasia type 2 is an inherited cancer syndrome characterized by tumors of thyroid and adrenal tissues. Germline mutations of the REarranged during Transfection (RET) proto-oncogene, leading to its unregulated activation, are the underlying cause of this disease. Multiple endocrine neoplasia type 2 has been a model in clinical cancer genetics, demonstrating how knowledge (...) of the genetic basis can shape the diagnosis and treatment of the disease. Here, we discuss the nature and effects of the most common recurrent mutations of RET found in multiple endocrine neoplasia type 2. Current understanding of the molecular mechanisms of RET mutations and how they alter the structure and function of the RET protein leading to its aberrant activation, and the effects on RET localization and signaling are described.

2012 Clinics PubMed abstract

188. JADA Continuing Education: Multiple endocrine neoplasia in an orthodontic patient: Interprofessional diagnostic and treatment implications. (Abstract)

JADA Continuing Education: Multiple endocrine neoplasia in an orthodontic patient: Interprofessional diagnostic and treatment implications. Multiple endocrine neoplasia, type 2B (MEN 2B), is an autosomal-dominant condition characterized by the development of multiple endocrine tumors. All affected people develop an aggressive form of medullary thyroid cancer (MTC). Without early prophylactic thyroidectomy, the prognosis for patients with MEN 2B is poor; the average age at death is 21 years.The

2012 Journal of the American Dental Association

189. Molecular Epidemiology of Multiple Endocrine Neoplasia 2: Implications for RET Screening in the New Millenium. (Full text)

Molecular Epidemiology of Multiple Endocrine Neoplasia 2: Implications for RET Screening in the New Millenium. Twenty years ago, the groundbreaking discovery that rearranged during transfection (RET) mutations underlie multiple endocrine neoplasia 2 (MEN2) and familial medullary thyroid cancer (FMTC) ushered in the era of personalized medicine. MEN2-associated signs, taking time to manifest, can be subtle. This study sought to clarify to what extent conventional estimates of 1:200 000-500 000 (...) in Germany is ∼1:80 000 inhabitants.The molecular minimum incidence estimate of ≈1:100 000 was two- to fivefold greater than conventional estimates of 1:200 000-500 000.

2012 European Journal of Endocrinology PubMed abstract

190. Multiple endocrine neoplasias: an overview of recent progress (Full text)

Multiple endocrine neoplasias: an overview of recent progress 22584697 2013 01 16 2018 11 13 1980-5322 67 Suppl 1 2012 Clinics (Sao Paulo, Brazil) Clinics (Sao Paulo) Multiple endocrine neoplasias: an overview of recent progress. 1 S1807-59322012001300001 Rocha-e-Silva Mauricio M Toledo Sergio P A SP eng Editorial Introductory Journal Article Brazil Clinics (Sao Paulo) 101244734 1807-5932 IM Humans Multiple Endocrine Neoplasia diagnosis genetics therapy 2012 5 16 6 0 2012 5 25 6 0 2013 1 17 6 0 (...) ppublish 22584697 S1807-59322012001300001 PMC3328815 Clinics (Sao Paulo). 2011;66 Suppl 1:3-17 21779718 Clinics (Sao Paulo). 2011;66 Suppl 1:19-24 21779719 Clinics (Sao Paulo). 2011;66 Suppl 1:25-32 21779720 Clinics (Sao Paulo). 2011;66 Suppl 1:71-7 21779725 Clinics (Sao Paulo). 2011;66 Suppl 1:45-54 21779722 Clinics (Sao Paulo). 2011;66 Suppl 1:55-63 21779723 Clinics (Sao Paulo). 2011;66 Suppl 1:65-9 21779724 Clinics (Sao Paulo). 2011;66 Suppl 1:33-43 21779721

2012 Clinics PubMed abstract

191. Multiple Endocrine Neoplasia, Type 1 (MEN 1)

Multiple Endocrine Neoplasia, Type 1 (MEN 1) Multiple Endocrine Neoplasia, Type 1 (MEN 1) - Endocrine and Metabolic Disorders - MSD Manual Professional Edition Brought to you by The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases The trusted provider of medical information since 1899 SEARCH SEARCH MEDICAL TOPICS Common Health Topics Resources QUIZZES & CASES Quizzes Cases / / / / IN THIS TOPIC OTHER (...) to a study published... 3D Model Female Endocrine System Video Overview of Physiologic pH and Buffers SOCIAL MEDIA Add to Any Platform Loading , MD, Northwestern University Feinberg School of Medicine Click here for Patient Education NOTE: This is the Professional Version. CONSUMERS: (See also .) Multiple endocrine neoplasia, type 1 (MEN 1) is a hereditary syndrome characterized by hyperplasia or sometimes adenomas of the parathyroid glands and tumors of the pancreatic islet cells and/or pituitary gland

2013 Merck Manual (19th Edition)

192. Oncogenetic testing for persons with hereditary endocrine cancer syndromes

assigned by CRD MeSH Adrenal Gland Neoplasms; Biomarkers, Tumor; Carcinoma; Endocrine Gland Neoplasms; Genetic Predisposition to Disease; Genetic Testing; Humans; Multiple Endocrine Neoplasia; Parathyroid Neoplasms; Pituitary Neoplasms; Thyroid Neoplasms Language Published English Country of organisation Belgium English summary An English language summary is available. Address for correspondence Belgian Health Care Knowledge Centre (KCE), Administrative Centre Botanique, Doorbuilding (10th floor (...) Oncogenetic testing for persons with hereditary endocrine cancer syndromes Oncogenetic testing for persons with hereditary endocrine cancer syndromes Oncogenetic testing for persons with hereditary endocrine cancer syndromes Vlayen J, Bex M, Bravenboer B, Claes K, Lapauw B, Persu A, Poppe K, Ullman U, Van Maerken T, Vroonen L, Poppe B Record Status This is a bibliographic record of a published health technology assessment from a member of INAHTA. No evaluation of the quality of this assessment

2015 Health Technology Assessment (HTA) Database.

193. Oncogenetic testing for persons with hereditary endocrine cancer syndromes

with the following selection of endocrine tumours / syndromes: ? Multiple Endocrine Neoplasia type 1 (MEN1) ? Multiple Endocrine Neoplasia type 2 (MEN2) ? Von Hippel-Lindau (VHL) syndrome ? Phaeochrom ocytoma ? Paraganglioma. Clinicians are encouraged to interpret these recommendations in the context of the individual person/patient situation, values and preferences. All KCE guidelines are as much as possible based on clinical evidence and may not always be in line with the current criteria for NIHDI (RIZIV (...) abnormalities including marfanoid body habitus) ? Familial MTC: family with at least 4 members diagnosed with MTC (in the absence of pheochromocytoma or parathyroid adenoma/hyperplasia)8 Oncogenetic testing in endocrine syndromes KCE Report 242Cs 4.2. Multiple Endocrine Neoplasia type 1 (MEN1) Multiple Endocrine Neoplasia type 1 (MEN1) is a polyglandular genetic syndrome characterized by tumours of the parathyroid glands, pancreatic islet cells and/or anterior pituitary gland. Parathyroid tumours

2015 Belgian Health Care Knowledge Centre

194. A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients

A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration (...) or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. A Phase 1, Randomized, Placebo-controlled, Multiple Dose Escalation Study to Investigate Safety, Pharmacokinetics, and Pharmacodynamics of SHR0534 in Chinese Type 2 Diabetic Patients The safety and scientific validity of this study is the responsibility of the study sponsor and investigators

2016 Clinical Trials

195. Pluriglandular syndrome: multiple endocrine neoplasia. (Full text)

Pluriglandular syndrome: multiple endocrine neoplasia. 6026898 1967 08 05 2018 11 13 0035-9157 60 7 1967 Jul 07 Proceedings of the Royal Society of Medicine Proc. R. Soc. Med. Pluriglandular syndrome: multiple endocrine neoplasia. 650-1 Anderson J J eng Journal Article England Proc R Soc Med 7505890 0035-9157 IM Blood Protein Disorders etiology Carcinoid Tumor surgery Celiac Disease etiology Humans Hyperparathyroidism etiology Intestinal Neoplasms surgery Male Mediastinal Neoplasms (...) complications Middle Aged Parathyroid Neoplasms complications Postoperative Complications 1967 7 7 1967 7 7 0 1 1967 7 7 0 0 ppublish 6026898 PMC2211636 Gastroenterology. 1960 Mar;38:458-66 13823205 Arch Surg. 1960 Sep;81:379-88 13827437 Thorax. 1962 Jun;17:120-7 14007148

1967 Proceedings of the Royal Society of Medicine PubMed abstract

196. Animal model of human disease. Medullary thyroid carcinoma, multiple endocrine neoplasia, Sipple's syndrome. Animal model: ultimobranchial thyroid neoplasm in the bull. (Full text)

Animal model of human disease. Medullary thyroid carcinoma, multiple endocrine neoplasia, Sipple's syndrome. Animal model: ultimobranchial thyroid neoplasm in the bull. 4811759 1974 04 02 2018 11 13 0002-9440 74 2 1974 Feb The American journal of pathology Am. J. Pathol. Animal model of human disease. Medullary thyroid carcinoma, multiple endocrine neoplasia, Sipple's syndrome. Animal model: ultimobranchial thyroid neoplasm in the bull. 377-80 Capen C C CC Black H E HE eng Journal Article (...) United States Am J Pathol 0370502 0002-9440 AIM IM Adenoma genetics pathology Animals Carcinoma pathology Cattle Cattle Diseases pathology Disease Models, Animal Humans Male Parathyroid Neoplasms genetics pathology Pheochromocytoma genetics pathology Syndrome Thyroid Neoplasms genetics pathology veterinary 1974 2 1 1974 2 1 0 1 1974 2 1 0 0 ppublish 4811759 PMC1910773 Cornell Vet. 1971 Oct;61(4):625-39 5166135 Cancer. 1973 Oct;32(4):865-78 4356482 Pathol Vet. 1969;6(1):1-14 5802694 Virchows Arch B

1974 The American journal of pathology PubMed abstract

197. Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes

, thyroid medullary cancer or familial history of multiple endocrine neoplasia type 2 Estimated glomerular filtration rate<60ml/min/ 1.73m2 (CKD-EPI method) Congestive heart failure Any uncontrolled disease, cancers essentially Chronic use of paracetamol containing products, which may falsely raise sensor glucose readings Use of tricyclic antidepressant, selective serotonin reuptake inhibitor, triptans, neuroleptic drugs and glucocorticoid. Patient who participated in another clinical trial (...) Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes Dulaglutide and Insulin MicrosecretiON in Type 1 Diabetes - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration or results information. Search for terms x × Study Record Detail Saved Studies Save this study Warning You have reached the maximum number of saved studies (100). Please remove one or more studies before adding more. Dulaglutide and Insulin MicrosecretiON

2018 Clinical Trials

198. Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1 (Full text)

, PHPT may further exacerbate the metabolic bone defect in these patients and should be treated when present according to published guidelines.Coexistence of PPGL and PHPT can occur in subjects with NF-1, mimicking multiple endocrine neoplasia type 2 (MEN2). (...) Concurrent primary hyperparathyroidism and pheochromocytoma in a Chinese lady with neurofibromatosis type 1 We report a case of elderly Chinese lady with neurofibromatosis type-1 presenting with longstanding palpitation, paroxysmal hypertension and osteoporosis. Biochemical testing showed mild hypercalcaemia with non-suppressed parathyroid hormone level suggestive of primary hyperparathyroidism, and mildly elevated urinary fractionated normetanephrine and plasma-free normetanephrine pointing

2018 Endocrinology, diabetes & metabolism case reports PubMed abstract

199. G-Pen Compared to Glucagen Hypokit for Severe Hypoglycemia Rescue in Adults With Type 1 Diabetes

(other than with suspect or documented hypoglycemia). Current bleeding disorder, treatment with warfarin, or platelet count below 50 × 109 per liter. History of pheochromocytoma or disorder with increased risk of pheochromocytoma (multiple endocrine neoplasia type 2 (MEN 2), neurofibromatosis, or Von Hippel-Lindau disease). History of insulinoma. History of allergies to glucagon or glucagon-like products, or any history of significant hypersensitivity to glucagon or any related products or to any (...) : Layout table for MeSH terms Diabetes Mellitus Diabetes Mellitus, Type 1 Hypoglycemia Glucose Metabolism Disorders Metabolic Diseases Endocrine System Diseases Autoimmune Diseases Immune System Diseases Glucagon Glucagon-Like Peptide 1 Gastrointestinal Agents Hormones Hormones, Hormone Substitutes, and Hormone Antagonists Physiological Effects of Drugs Incretins

2018 Clinical Trials

200. Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliquaâ„¢) in Patients With Type 2 Diabetes Mellitus (T2DM)

Personal or immediate family history of medullary thyroid cancer or genetic conditions that predispose the patient to medullary thyroid cancer (e.g. multiple endocrine neoplasia syndromes) The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial. Contacts and Locations Go to Information from the National Library of Medicine To learn more about this study, you or your doctor may contact the study research staff using (...) Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliquaâ„¢) in Patients With Type 2 Diabetes Mellitus (T2DM) Study Comparing the Efficacy and Safety of Insulin Glargine (Basal Insulin)/Lixisenatide (GLP-1 Receptor Agonist) Combination (Soliqua™) in Patients With Type 2 Diabetes Mellitus (T2DM) - Full Text View - ClinicalTrials.gov Hide glossary Glossary Study record managers: refer to the if submitting registration

2018 Clinical Trials

To help you find the content you need quickly, you can filter your results via the categories on the right-hand side >>>>